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Na+,K+-ATPase is an ubiquitous membrane enzyme
that allows the extrusion of three sodium ions from the cell
and two potassium ions from the extracellular ﬂuid. Its ac-
tivityisdecreasedinmanytissuesofstreptozotocin-induced
diabetic animals. This impairment could be at least partly
responsible for the development of diabetic complications.
Na+,K+-ATPase activity is decreased in the red blood cell
membranesoftype1diabeticindividuals,irrespectiveofthe
degree of diabetic control. It is less impaired or even nor-
mal in those of type 2 diabetic patients. The authors have
shown that in the red blood cells of type 2 diabetic patients,
Na+,K+-ATPase activity was strongly related to blood C-
peptide levels in non–insulin-treated patients (in whom C-
peptide concentration reﬂects that of insulin) as well as in
insulin-treated patients. Furthermore, a gene-environment
relationship has been observed. The alpha-1 isoform of the
enzyme predominant in red blood cells and nerve tissue is
encodedbytheATP1A1gene.Apolymorphismintheintron
1 of this gene is associated with lower enzyme activity in pa-
tients with C-peptide deﬁciency either with type 1 or type
2 diabetes, but not in normal individuals. There are several
lines of evidence for a low C-peptide level being responsi-
ble for low Na+,K+-ATPase activity in the red blood cells.
Short-term C-peptide infusion to type 1 diabetic patients
restores normal Na+,K+-ATPase activity. Islet transplan-
tation, which restores endogenous C-peptide secretion, en-
hances Na+,K+-ATPase activity proportionally to the rise
in C-peptide. This C-peptide effect is not indirect. In fact,
incubation of diabetic red blood cells with C-peptide at
physiologicalconcentrationleadstoanincreaseofNa+,K+-
ATPase activity. In isolated proximal tubules of rats or
in the medullary thick ascending limb of the kidney,
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C-peptidestimulatesinadose-dependentmannerNa+,K+-
ATPaseactivity.ThisimpairmentinNa+,K+-ATPaseactiv-
ity, mainly secondary to the lack of C-peptide, plays prob-
ably a role in the development of diabetic complications.
Arguments have been developed showing that the diabetes-
induced decrease in Na+,K+-ATPase activity compromises
microvascular blood ﬂow by two mechanisms: by affecting
microvascular regulation and by decreasing red blood cell
deformability, which leads to an increase in blood viscos-
ity. C-peptide infusion restores red blood cell deformability
andmicrovascularbloodﬂowconcomitantlywithNa+,K+-
ATPase activity. The defect in ATPase is strongly related to
diabetic neuropathy. Patients with neuropathy have lower
ATPase activity than those without. The diabetes-induced
impairment in Na+,K+-ATPase activity is identical in red
blood cells and neural tissue. Red blood cell ATPase activ-
ity is related to nerve conduction velocity in the peroneal
and the tibial nerve of diabetic patients. C-peptide infusion
todiabeticratsincreasesendoneuralATPaseactivityinrat.
BecausethedefectinNa+,K+-ATPaseactivityisalsoproba-
blyinvolvedinthedevelopmentofdiabeticnephropathyand
cardiomyopathy, physiological C-peptide infusion could be
beneﬁcial for the prevention of diabetic complications.
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Recently, several investigators have shown that C-peptide
administration exercised some beneﬁcial effects in humans or
animal affected by insulinopenic diabetes and lacking both
C-peptide and insulin. Among these effects, a stimulation of
Na+,K+-ATPase activity in various tissues has been described.
It is known that Na+,K+-ATPase activity is impaired in the
cell membrane of many tissues obtained from diabetic individ-
uals or animals and this defect may play a role in the devel-
opment of the complication of diabetes. This review will deal
with the diabetes-induced alteration of Na+,K+-ATPase activ-
ity, its relationship with C-peptide level, the effect of C-peptide
administration on Na+,K+-ATPase activity in diabetes, and the
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possible relevance of these ﬁndings to the comprehension of,
and the therapeutic approach to prevent or treat, the long-term
complications of diabetes.
THE SODIUM-POTASSIUM ATPase
Introduction
The sodium-potassium adenosine triphosphatase (Na+,K+-
ATPase; sodium pump; EC 3.6.1.37) is an ubiquitous
membrane-associatedproteincomplexthatisexpressedinmost
eukaryotic cells. The “pump” transduces energy from the intra-
cellularhydrolysisofadenosinetriphosphate(ATP)totheactive
countertransportofsodiumandpotassiumacrossthecellmem-
brane (Clausen et al., 1991). The Na+,K+-ATPase contains 1
principal catalytic subunit, designated α and 1 sugar-rich aux-
iliary subunit, designated β. There is an associated subunit γ
present only in some tissues, the 3 subunits occurring in a 1:1:1
ratio (Forbush et al., 1978; Jorgensen, 1982).
The α subunit has a molecular mass of about 110 kDa with
10 transmembrane segments. Four distinct isoforms have been
identiﬁed. The differences of amino acid sequences among the
isoforms are minor. They are each coded by a different gene,
some of them located on different chromosomes (Sweadner,
1989; Mercer, 1993). The various isoforms differ primarily in
their tissue distribution, α1 predominating in several tissues,
including kidney, nerves, and lung; α2 in skeletal muscle and
heart; α3 in the brain; and α4, which is apparently localized
to testis and speciﬁcally to spermatozoa (Kaplan, 1985). The
α subunit carries the catalytic function of the enzyme, and this
is reﬂected in its possession of several binding and functional
domains.
The β subunit has a molecular mass of about 55 kDa, with
a single membrane crossing. Three isoforms have been identi-
ﬁed. As α isoforms, β isoforms have a tissue-speciﬁc distribu-
tion, β1 is ubiquitous, β2 is expressed in skeletal muscle and
heart, and β3 in testis and central nervous system (Kotyk and
Amler, 1995). It is clear that an essential role for β subunit is
in the delivery and the appropriate insertion of α subunit in the
membrane (McDonough et al., 1990). In recent years, a variety
of studies suggest that the β subunit may be more intimately
involved in the mechanism of active transport and may be a
regulatory subunit (Kaplan, 1985; Geering, 2001).
The γ subunit is a hydrophobic and a single-membrane-
crossing protein of molecular mass about 12 kDa. Although
very little is known about its function, it does appear to be obli-
gatorily associated with the αβ complex (Therien et al., 1997).
Na+,K+-ATPase couples the energy released in the intra-
cellular hydrolysis of ATP to the export of three intracellu-
lar sodium ions and the import of two extracellular potassium
ions.Thecontinuousoperationofthismacromolecularmachine
ensures the generation and maintenance of concentration gra-
dients of sodium and potassium across the cell membrane. This
electrochemical gradient provides energy for the membrane
transport of metabolites, nutrients, and ions. This electrochem-
ical gradient is essential also for regulation of cell volume and
intracellularpHandfortheactionpotentialofmuscleandnerve
(Therienetal.,1997).Thisenzymeisresponsibleofabout15%
to20%ofrestingenergeticexpenseinwholeorganism(Clausen
et al., 1991).
Because several cellular transport systems are coupled to
the movement of sodium and, therefore, to the function of
Na+,K+-ATPase, this enzyme is the target of multiple regu-
latory mechanisms activated in response to changing cellular
requirements. The requirement for modulators of the Na+,K+-
ATPase is likely to be greatest in tissues in which perturbations
oftheintracellularalkalicationconcentrationunderlietheirspe-
cialized functions. Prime examples are the changes in enzyme
activity that occur in response to physiological stimuli such as
nerve impulse propagation and exercise (Therien et al., 1997).
In general, regulation of Na+,K+-ATPase is brought about by
increased message transcription, increased recruitment of het-
erodimers to the cell membrane, alterations of heterodimers
trafﬁcking, and half-life in the cell membrane, and by direct
regulation of enzymes in the cell membrane. Direct regulation
of the cell membrane enzymes results from phosphorylation
and dephosphorylation by protein kinases and protein phos-
phatases. Thus, depending on the tissue, activation of protein
kinases can induce an increase or decrease in sodium pump
activity (Ewart and Klip, 1995). Moreover, sodium pump regu-
lation seems to be tissue but also isoform speciﬁc (Feraille and
Doucet, 2001).
Firstly, the simplest and most straightforward determinants
of pump activity are the concentrations of substrates, i.e.,
sodium, potassium, and ATP. Some hormones appear to al-
ter Na+,K+-ATPase activity by changing its apparent afﬁn-
ity for sodium or by increasing the sodium inﬂux. The ATP
concentration is generally saturating for the enzyme in most
cells. However, in some tissues and under certain conditions,
ATP levels may fall to subsaturating levels, such as in kidney
medulla, which functions under near anoxic conditions (Brezis
and Rosen, 1995).
Secondly, endogenous cardiotonic steroids such as ouabain
inhibits speciﬁcally the sodium pump, whereas interactions of
the pump with components of the cytoskeleton allows the cor-
rect processing and targeting of sodium pumps to the appropri-
ate membrane compartment (Therien et al., 1997).
Thirdly, Na+,K+-ATPase is a transmembranous enzyme
and many reports have focused on the role of membrane
lipids. In general, lipids that promote bilayer formation of
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optimal Na+,K+-ATPase activity, as do negatively charged
lipids such as phosphatidylserine and phosphatidylglycerol
(Kimelberg & Papahadjopoulos, 1972; Kimelberg, 1975;
Johannson et al., 1981). The effects of cholesterol on enzyme
activity are often also related to membrane ﬂuidity (Giraud
et al., 1981). Free fatty acids present in the membranes or as
the products of phospholipases and eicosanoids tend to have
various regulatory effects on Na+,K+-ATPase activity.
Lastly, the enzyme activity is subjected to both short- and
long-term regulation by several hormones. Short-term regula-
tion involves generally direct effects on the kinetic behavior
of the enzyme or translocation of sodium pumps between in-
tracellular stores and the plasma membrane. Long-term reg-
ulation induces de novo Na+,K+-ATPase synthesis or degra-
dation. Corticosteroids and particularly aldosterone sustains a
long-term increase in expression of sodium pumps, whereas
catecholamines have various affects on pump activity, with
an inhibitory effect of dopamine and a stimulating effect of
epinephrine and norepinephrine (Therien et al., 1997). Insulin
mainly stimulates the Na+,K+-ATPase activity by increasing
the translocation of sodium pumps from intracellular stores
to the cell surface, the cytoplasmic sodium content, and also
the apparent afﬁnity of the enzyme for sodium (Sweeney and
Klip, 1998). Recently, C-peptide has been found to stimulate
the Na+,K+-ATPase activity in renal tubular from control rat
(Ohtomo et al., 1996) and in sciatic nerve from diabetic rat
(Ido et al., 1997). In human diabetes, the decrease of avail-
ability of both insulin and C-peptide could change the regu-
latory equilibrium of Na+,K+-ATPase activity in favor of a
decrease.
The human genome appears to contain at least ﬁve distinct
α subunit and related genes, each 20 to 25 kb in length. α1, α2,
and α4 are coded by ATP1A1, ATP1A2, and ATP1AL2 genes
respectively located on chromosome 1, whereas α3 is coded by
ATP1A3genelocatedonchromosome19.Thereisalsoarelated
gene, ATP1AL1, located on chromosome 13, with no transcrip-
tionofamRNAbecauseofalackoffunctionalpromoterregion
(Yang-Feng et al., 1988; Modyanov et al., 1991; Shamraj and
Lingrel,1994).Somepolymorphismshavebeenidentiﬁedonα
genes,andparticularly,onATP1A1,whichpresentsarestriction
polymorphism with Bgl II enzyme (Shull et al., 1990).
The multiple β isoforms are products of separate genes,
about8kbinlength,whicharedispersedinthehumangenome.
β1, β2, and β3 are coded by ATP1B1, ATP1B2, and ATP1B3,
respectively, and located on chromosomes 1, 17, and 9 (Avila
et al., 1998; Mobasheri et al., 2000). A related gene, ATP1BL1,
has been identiﬁed on chromosome 4 but seems to be not ex-
pressed (Yang-Feng et al., 1988). In parallel with α subunits,
somepolymorphismshavebeenidentiﬁedtooonβ genes(Shull
et al., 1990).
Diabetes-Induced Alterations
in Na+,K+-ATPase Activity
Diabetes has a marked effect on the metabolism of a vari-
etyoftissuesandbecausetheNa+,K+-ATPaseiscriticalforthe
membranepotentialandmanytransports,achangeinitsactivity
in diabetes would have profound consequence in these tissues.
Streptozotocin- and alloxan-treated or genetically susceptible
diabeticrodentsareanimalmodelsusedtoassessmetabolicand
physiological changes induced by insulin-dependent diabetes.
Among the diabetes-induced metabolic changes, disturbances
of Na+,K+-ATPase activity have been widely reported (Sima
andSugimoto,1999).Dasandcolleagues(1976)ﬁrstdescribed
a decrease of this enzyme activity in sciatic nerve of diabetic
rat, whereas an increase in enzyme activity was found in mu-
cosa of the small intestine of diabetic rat (Gnanaprakasam and
Srivastava, 1978). These two examples illustrate the different
effectofdiabetesonNa+/K+-ATPasedependingonthetissues.
Tissues can be classiﬁed in three groups, one principal group
in which diabetes induces a decrease in Na+,K+-ATPase activ-
ity,includingsciaticnerve,lens,heart,anderythrocyte;another
group in which diabetes causes an increase in enzyme activity,
including mucosa of the small intestine; and one group with a
Na+,K+-ATPase activity unchanged or where it exists differ-
ences between studies. The last group includes tissues such as
brain and kidney. All the tissues variations in Na+,K+-ATPase
activity in diabetic rat are summarized in Table 1.
Various mechanisms have been suggested to explain the de-
creaseinNa+,K+-ATPaseactivity:adepletionoftheintracellu-
larpoolofmyo-inositol,anincreasedﬂuxthroughthealdosere-
ductasepathway,andanalterationinproteinkinaseC(PKC)ac-
tivity (Greene et al., 1987). Others diabetes-induced metabolic
changes can also down-regulate the enzyme activity, includ-
ing the increase in oxidative stress, the formation of advanced
glycation products, the nerve growth factor metabolism (Sima
andSugimoto,1999),andthedisturbanceinessentialfattyacid
metabolismleadingtoanabnormalω6/ω3ratioinredbloodcell
membrane (Djemli-Shipkolye et al., 2003). Moreover, insulin
andC-peptidedeﬁcienciescanalterthelong-termregulationof
enzyme units expressed at the cell surface. Indeed, some stud-
ies have found signiﬁcant decreases in mRNA levels of one
to four subunits in aorta and left ventricle as soon as 14 days
after diabetes induction (Ohara et al., 1991; Ver et al., 1997).
Interestingly, Nishida and colleagues (1992) have shown that
in skeletal muscle of diabetic rat, mRNA level of α1 was un-
changed, whereas mRNA level of α2 was increased 14 days af-
ter diabetes induction. However, Na+,K+-ATPase activity was
diminished because of a signiﬁcant decrease in mRNA level
of the β1 isoform (Nishida et al., 1992). The last point shows
that overexpression of α isoforms cannot be connected with an
increase in enzyme activity; β isoforms are necessary to form40 P. VAGUE ET AL.
TABLE 1
Variations in Na+,K+-ATPase activity in different tissues of insulinopenic diabetic rat
Tissue Na+,K+-ATPase activity Reference
Brain, nervous system, and glands
Brain ⇔ Mayanil et al., 1982
Brain ⇓ Ver et al., 1995a
Dorsal root ganglia ⇓ Green et al., 1985
Hippocampus, cerebral cortex ⇓ Leong and Leung, 1991
Thalamus, hypothalamus, brain stem ⇓ Leong and Leung, 1991
Striatum, cerebellum ⇔ Leong and Leung, 1991
Superior cervical ganglion ⇓ Greene and Mackway, 1986
Lens ⇓ Ahmad et al., 1985
Retinal pigmented epithelium ⇓ McGregor et al., 1986
Sciatic nerve ⇓ Das et al., 1976
Vagal nerve ⇓ Nowak et al., 1995
Heart
Heart sarcolemma ⇓ Pierce and Dhalla, 1983
Heart ventricular muscle ⇓ Kjeldsen et al., 1987
Intestine
Mucosa of the small intestine ⇑ Gnanaprakasam and Srivastava, 1978
Mucosa basolateral membrane ⇑ Luppa and Muller, 1986
Mucosa brush border region ⇔ Luppa and Muller, 1986
Kidney
Whole kidney ⇑ Clark et al., 1983
Collecting tubule ⇑ Trinh-Trang-Tan et al., 1985
Cortical thick ascending limb ⇔ Trinh-Trang-Tan et al., 1985
Glomeruli (isolated) ⇓ Cohen et al., 1985
Medullary thick ascending limb ⇔ Trinh-Trang-Tan et al., 1985
Medullary thick ascending limb ⇓ Tsimaratos et al., 2001
Renal medulla and cortex ⇑ Wald and Popovtzer, 1984
Renal tubule ⇑ Ku et al., 1986
Others tissues
Aorta ⇓ Ohara et al., 1991
Erythrocyte ⇓ Agarwal et al., 1985
Hepatocyte ⇓ Carnovale et al., 1991
Liver ⇑ Sennoune et al., 2000
Skeletal muscle ⇓ Kjeldsen et al., 1987
⇑ increased; ⇓ decreased; ⇔ unchanged.
an active complex. It will be shown below that C-peptide has
short-term effect or Na+,K+-ATPase activity by modifying its
phosphorylation status.
Contrary to the down-regulation mechanisms, the mecha-
nisms implicated in the Na+,K+-ATPase increase in some tis-
sues of diabetic rat seems to be related to variations on mRNA
levelsofNa+,K+-ATPaseisoforms.Forexample,insmallintes-
tine, an increase in Na+,K+-ATPase activity is correlated with
an increase in mRNA levels of α1 and β1 isoforms (Fedorak
et al., 1991; Barada et al., 1994). In kidney, Ver and colleagues
(1995b) have shown that mRNA levels of α1 and β1 isoforms
increased in medulla but not in cortex, whereas there was a
highly signiﬁcant linear correlation between Na+,K+-ATPase
activity and mRNA level of α1 isoforms in all the nephron
segments in the study of Scherzer and Popovtzer (2002). The
discrepancies in enzyme activity observed in the diabetic kid-
ney can be attributed to time-dependent changes in Na+,K+-
ATPaseactivityandexpression.Earlyrenalhypertrophyindia-
betic rat enhances Na+,K+-ATPase activity in several nephron
segmentssecondarytoarecruitmentofenzymestoresandanin-
creaseintheamountofα1andβ1subunits.Long-termdiabetes
(12weeksandmore)candecreasetheNa+,K+-ATPaseactivity,
with a reduction in α1 and β1 isoforms abundance, particularly
in medullary thick ascending limb (Tsimaratos et al., 2001).C-PEPTIDE, Na+,K+-ATPase, AND DIABETES 41
Na+,K+-ATPase Abnormalities
in Human Diabetes
In human individuals, the vast majority of the studies have
been done on erythrocyte, except for a few on nerve biopsies
(Scarpini et al., 1993). The red blood cell (RBC) Na+,K+-
ATPase activity reﬂects that of the sciatic nerve (Raccah et al.,
1996b).AsshowninTable1,diabetesinducesadecreaseinthe
enzyme activity in almost all the tissues as well as in erythro-
cytes. Therefore, it seems reasonable to suggest that Na+,K+-
ATPase activity data obtained from RBCs may be extrapolated
to the enzyme status in other tissues, specially in nerve tissue.
Earlier studies (Finotti and Verbaro, 1987; Rahmani-
Jourdheuil et al., 1987) have shown that in patients affected by
type 1 diabetes, RBC Na+,K+-ATPase activity was decreased,
as it is in diabetic animals. In type 1 diabetic individuals, RBC
Na+,K+-ATPase activity is on the average 30% lower that in
appropriate control individuals (Figure 1). Various approaches
may be used to estimate the enzyme function, which may be
done by measuring ATP hydrolysis by red blood cell mem-
brane(Raccahetal.,1992),sodiumefﬂux(FinottiandVerbaro,
1987), rubidium inﬂux (Kimelberg and Mayhew, 1975), or en-
ergy expenditure by a microcaloric method (Issautier et al.,
1994) in living RBCs. Comparable results have been obtained
with all these techniques, mainly a 30% decrease in enzyme
activity in RBCs from diabetic patients compared to control
individuals.
FIGURE 1
Erythrocyte Na+,K+-ATPase activity in the different groups of control subjects and type 1 and type 2 diabetic patients. From
Dufayet de la Tour et al., 1998.
The impaired enzyme activity does not appear linked to a
lower number of enzyme units in the RBC membrane as esti-
mated by [3H]ouabain binding (Raccah et al., 1996a). No cor-
relation was observed between RBC Na+,K+-ATPase activity
and the degree of metabolic control estimated by actual blood
glucose or HbA1c nor with cholesterol or triglyceride levels,
insulinrequirement,orbodymassindex(Raccahetal.,1996b).
Therefore, hyperglycemia does not appear directly responsi-
ble for the changes in enzyme activity. As it will be described
below, C-peptide deﬁciency appears strongly implicated.
Anotherargumenttoexcludeadirectresponsibilityofhyper-
glycemia is that in type 2 diabetic individuals, RBC Na+,K+-
ATPase activity is much less impaired, as shown on Figure 1.
In fact, it appears in the normal range in the groups of individ-
uals treated by diet alone or oral agents, and impaired in the
insulin-treated group only.
Genetic Control of Na+,K+-ATPase Activity
SeveralﬁndingssuggestthatNa+,K+-ATPaseactivityisun-
der genetic control. It is lower in men (Lasker et al., 1985).
Strong familial inﬂuence and ethnic differences have been
noted, with lower levels being observed in blacks, Asians, and
Jewish subjects in comparison to Scandinavians (Beutler et al.,
1983;Laskeretal.,1985).Havingobservedthattype1diabetic
individualsofNorthAfricanancestrypresentwithanincreased
prevalence of polyneuropathy than their European counterpart42 P. VAGUE ET AL.
(Vague et al., 1988), and suspecting the role of a decreased
Na+,K+-ATPaseactivityinthiscomplication,weobservedthat
RBC Na+,K+-ATPase activity was lower in subjects of North
African ancestry, either healthy or diabetic, compared to their
appropriateEuropeancontrols.Thisphenomenonappearstobe
related to a decrease in a number of enzyme units in the RBC
membrane, as estimated by a lower number of ouabain binding
sites (Vague et al., 1997b).
As mentioned above, a polymorphism with a variant allele
frequency around 0.1 has been described in the intron 1 of the
ATPA1 gene encoding for the α1 isoform, major isoform of the
α subunit,whichistheonlyonepresentinredbloodcells.RBC
Na+,K+-ATPase activity does not differ between nondiabetic
individuals bearing or not the variant allele. However, among
diabeticsubjects,RBCATPaseactivityisevenlowerinsubjects
withthevariantallele(Jannotetal.,2002).Thepresenceofthis
allele could confer a genetic predisposition to some diabetic
complications (Vague et al., 1997a).
RELATIONSHIP BETWEEN Na+,K+-ATPase
AND C-PEPTIDE IN DIABETES
The diabetes-induced impairment in Na+,K+-ATPase activ-
ity could be related to hyperglycemia via an increased glycosy-
lation of its β subunit involved in the maturation of the enzyme
and its localization and stabilization in the plasma membrane
(Eakle et al., 1994). The defect in myo-inositol metabolism
leading to altered lipid metabolism in the membrane and by the
way decreased Na+,K+-ATPase activity could also be involved
(Yorek et al., 1988). However, a direct action of hyperglycemia
on this enzyme activity has never been conﬁrmed.
In type 1 diabetic patients, RBC Na+,K+-ATPase activity is
not related to actual plasma glucose, nor HbA1c value, plasma
triglyceride, or total cholesterol (Raccah et al., 1996b). More
in type 2 diabetes, this enzyme activity is much less impaired
than in type 1 diabetes in spite of similar HbA1c values (Jannot
et al., 2002). The same has been observed for the sciatic nerve
Na+,K+-ATPase activity in type 2 diabetic BBZDR rats com-
pared to type 1 diabetic BB rats (Sima et al., 2000).
Therefore,hyperglycemiapersedoesnotseemtoberespon-
sible for the impairment in Na+,K+-ATPase activity.
Among type 2 diabetic patients, the only parameter found to
be independently associated with RBC Na+,K+-ATPase activ-
ity was the plasma C-peptide concentration (Table 2, Figure 2;
Dufayet de la Tour et al., 1998). Because C-peptide is cose-
creted with insulin and the plasma C-peptide level reﬂects that
of insulin, a relation between C-peptide and Na+,K+-ATPase
activity could reﬂect in fact a relationship with insulin. How-
ever, Figure 2 shows that the relationship between C-peptide
and Na+,K+-ATPase activity in type 2 diabetic patients per-
sists among insulin-treated patients and is even stronger in this
TABLE 2
Stepwise regression analysis of the correlation between
erythrocyte Na+,K+-ATPase activity and the different
parameters in type 2 diabetic patients
Correlation
coefﬁcient FP value
C-peptide .48 7.7 .002
Age −.2 3.4 NS
Diabetes duration −.17 1.9 NS
Type of treatmenta .09 0.04 NS
HbA1c −.089 0.04 NS
BMI −.087 0.03 NS
Note. From Dufayet de la Tour et al., 1998.
aInsulin or oral hypoglycemic agents.
subgroup(r=.64versus.41forallgroups),establishingclearly
thatRBCNa+,K+-ATPaseactivityisrelatedtoC-peptidelevels
and not to insulin levels.
The presence of a variant allele of the ATP1A1 gene encod-
ingfortheα1isoformoftheNa+,K+-ATPaseisassociatedwith
lower Na+,K+-ATPase activity in type 1 diabetic patients but
not in control subjects (Vague et al., 1997a), which means that
the presence of the variant allele makes ATPase activity more
sensitive to the deleterious effect of diabetes, this effect being
probably secondary to the lack of C-peptide. And, in fact, we
have observed that in type 2 diabetic individuals, ATPase activ-
ity is dependent both on the presence of the variant allele and
C-peptide levels (Jannot et al., 2002).
Its seems clearly demonstrated that low Na+,K+-ATPase
activity in RBCs and sciatic nerves of diabetic individuals is
relatedtolowC-peptidelevels.Isthisrelationshipacausalone?
EFFECT OF C-PEPTIDE ADMINISTRATION
ON Na+,K+-ATPase ACTIVITY
In Vivo Effect
Patients affected by type 1 diabetes and who were C-peptide
negative received after a fasting period of about 5 hours a
continuous infusion of either C-peptide or placebo. C-peptide
was infused at a concentration of 3 pmol/min−1kg−1 for the
ﬁrst 60 minutes, then at a concentration of 10 pmol−1kg−1
for another 6 minutes (Forst et al., 2000). C-peptide levels
reached a maximum of 1.2 ± 0 nmol·L−1 at the end of the ﬁrst
infusion period and 3.5 ± 0.3 nmol·L−1 after 120 minutes.
These values are in the physiological fasting and postprandial
range, respectively.
Levels of erythrocyte Na+,K+-ATPase activity increased
during the C-peptide infusion by 83.3 ± 34.1 nmol Pi h−1
per mg protein during the low infusion rate and by 146 ±
6.9nmolPih−1permgproteinduringthehighinfusionrate.TheC-PEPTIDE, Na+,K+-ATPase, AND DIABETES 43
FIGURE 2
Correlation between fasting C-peptide and erythrocyte Na+,K+-ATPase activity among the type 2 diabetic patients.◦ Type 2
diabetic patients on oral treatment.• Type 2 diabetic patients on insulin treatment.
percentage increase in enzyme activity during the two periods
were respectively 62% ± 14% and 113% ± 20%. Although
Na+,K+-ATPase activity increased slightly during saline infu-
sion, the changes were not signiﬁcant.
In Vitro Effect
This effect of C-peptide on erythrocyte Na+,K+-ATPase
activity in vivo could be direct or indirect. It is in fact a direct
one. Erythrocytes obtained from C-peptide–negative diabetic
patients were resuspended in saline to eliminate leukocytes
and platelets and ﬁltered trough a cellulose microcrystalline
column. They were then incubated in a water bath at 37◦C with
C-peptide (6 nmol/L) for 10 minutes. Na+,K+-ATPase activity
wassigniﬁcantlyincreasedinthepresenceofC-peptide(363±
30 versus 255 ± 22 nmol/Pi/mg protein/h; P = .002 n = 14)
(Djemli-Shipkolye et al., 2000). The values, which were lower
than normal, in the “diabetic” range, returned to the normal
range.
Renal tubular cells reabsorb a huge amount of sodium
in part through Na+,K+-ATPase activity. Accordingly, they
are a rich source of Na+,K+-ATPase. The basic function
of the Na+,K+-ATPase is to maintain high sodium and
potassium gradients across the plasma membrane of animal
cells (for review, see Feraille and Doucet, 2001). Indeed, in
rat proximal convoluted tubule (Ohtomo et al., 1996, 1998)
and in medullary thick ascending limb (MTAL) (Tsimaratos
et al., 2003), C-peptide induced a dose-dependent stimulation
of Na+,K+-ATPase activity.
These results were also reported with ouabain-sensitive up-
take of rubidium-86, a marker of Na+,K+-ATPase activity, in
primary culture of human renal tubular cells (Johansson et al.,
2002) and in native rat MTAL tubules (Tsimaratos et al., 2003)
after exposure to autologous C-peptide.
MECHANISMS BY WHICH C-PEPTIDE
STIMULATES Na+,K+-ATPase ACTIVITY
Almost of all these studies were performed on renal tubular
cells in which Na+,K+-ATPase is particularly abundant and
deeply involved in the main physiological function of these
cells, i.e., the reabsorption of sodium.
Signal Transduction Pathway
The signal transduction pathway is thought to involve a
G-protein–coupled receptor because Na+,K+-ATPase activity
was abolished when renal tubules were incubated with pertus-
sis toxin (Ohtomo et al., 1996). In the same experiment and in
others, there was evidence that the effect observed was depen-
dent on a rise of intracellular calcium (Ohtomo et al., 1996;
Shafqat et al., 2002). Accurately, the C-peptide–induced in-
crease of intracellular calcium is mediated by a calcium in-
ﬂux because EGTA abolished its effect (Ohtomo et al., 1996).
Furthermore, pertussis toxin inhibited both C-peptide–induced
Na+,K+-ATPase activation and an increase in intracellular cal-
cium concentration (Agarwal et al., 1985), suggesting a link
between these two processes. Interestingly, C-peptide stim-
ulated speciﬁcally the classical PKC-α, calcium-dependent44 P. VAGUE ET AL.
mediator of Na+,K+-ATPase phosphorylation in tubular cells
(Tsimaratos et al., 2003). PKC-δ,- ε,- ς, which are also ex-
pressedinthisnephronsegment,werenotaffectedbyC-peptide
stimulation.
Because C-peptide speciﬁcally stimulated Na+,K+-ATPase
and PKC-α translocation in MTAL cells, and because PKC
phosphorylates tubular Na+,K+-ATPase (Feraille et al., 1995),
the effect of GF109203X, a speciﬁc inhibitor of PKCs, was ex-
amined. GF109203X completely abolished C-peptide–induced
Na+,K+-ATPase activity together with PKC translocation.
In addition to PKC activation, calcium-dependent mitogen-
associatedproteinkinaseactivation(MAPK)ERK1and2phos-
phorylation, abolished by pertussis toxin, was described in cul-
tured cells of mouse embryonic ﬁbroblast cell line (Swiss 3T3)
(Kitamura et al., 2001), and in human tubular cells (Johansson
et al., 2002). The latter argues for a possible recruitment of
tissue-speciﬁc intracellular effectors of Na+,K+-ATPase acti-
vation, rather than direct effect of PKC.
The contribution of adenyl cyclase activation to C-peptide
effect was observed in cultured cells (Kitamura et al., 2001),
butnotinnativeMTALcells,becausephysiologicalamountsof
C-peptide failed to increase the cellular cAMP release through
adenyl cyclase activity (Tsimaratos et al., 2003). These results
were consistent with the lack of increase of Na+,K+-ATPase
amount to membrane in response to C-peptide in MTAL
(Tsimaratos et al., 2003), because in this segment the protein
kinaseA(PKA/cAMP)pathwayresultsinrecruitmentofactive
Na+,K+-ATPase units (for review, see Feraille and Doucet,
2001).
Na+,K+-ATPase Phosphorylation
There is now evidence that C-peptide effect on Na+,K+-
ATPase activity is mediated in part by phosphorylation of the
catalytic α subunit.
Incubation of native MTAL tubules with physiologi-
cal amounts of C-peptide resulted in phosphorylation of
Na+,K+-ATPase catalytic subunit, which was abolished after
GF109203X preincubation of tubules, indicating that the ef-
fect of C-peptide on Na+,K+-ATPase activity was dependent
on PKC-α–dependent phosphorylation of the catalytic subunit
(Tsimaratos et al., 2003).
C-peptide Receptor
The stimulatory effect of C-peptide on Na+,K+-ATPase
was concentration dependent, and abolished by pertussis toxin
(Ohtomo et al., 1996; Tsimaratos et al., 2003). The kinetics
studies showed that physiological amounts of C-peptide
increased Na+,K+-ATPase activity after 5 minutes and that
this effect reached a plateau from 15 to 60 minutes (Tsimaratos
et al., 2003).
Therefore, the mechanism involved in C-peptide effect was
thought to be secondary to a speciﬁc linkage of C-peptide to
renalcells.BecausepertussistoxininhibitedC-peptideeffectin
variouscells(Ohtomoetal.,1996;Rigleretal.,1999;Johansson
et al., 2002), the receptor was suspected to be a G-protein–
type receptor, resulting in calcium inﬂux and PKC and MAPK
activation.
Altogether, these arguments are in favor of a speciﬁc hor-
monaleffectinrenalcellswhereC-peptidestimulatesNa+,K+-
ATPase activity (Ohtomo et al., 1996; Johansson et al., 2002;
Tsimaratos et al., 2003), PKC-δ (Tsimaratos et al., 2003), cal-
cium inﬂux (Shafqat et al., 2002), and activation of MAPK
(Kitamura et al., 2001; Johansson et al., 2002), but not PKA
(Tsimaratos et al., 2003). Furthermore, pertussis toxin inhibits
most of these effects, suggesting that C-peptide binds to trans-
membrane G-protein–coupled receptors with the α-subunit of
the Gi/G0 subtype. Activation of PKC and phosphoinositide
3-kinase (PI3K) is likely to be involved in C-peptide–induced
phosphorylation of MAPKs (Kitamura et al., 2001). However,
C-peptidespeciﬁcallyincreasedtheamountsofcellmembrane–
associated PKC-α (an index of its activation; Karim et al.,
1995), whereas the amounts of membrane-associated PKC-δ
and PKC-ς isoforms remained unaltered (Tsimaratos et al.,
2003). The speciﬁc PKC activation (Tsimaratos et al., 2003) is
consistent with the effect of C-peptide on Na+,K+-ATPase ac-
tivity,dependingonthepertussistoxin–sensitiveG-protein,and
on an increase in intracellular calcium concentration (Ohtomo
et al., 1996). In addition, GF109203X abolished Na+,K+-
ATPase activation and phosphorylation induced by C-peptide
when used at concentrations that inhibit classical and novel
PKCs but not atypical PKCs (Martiny-Baron et al., 1993). To-
gether with its saturable effect, these ﬁndings strongly suggest
thatC-peptideactsthroughaG-protein–coupledreceptorlinked
to the classical PKC-α pathway in rat MTAL.
C-PEPTIDE, Na+,K+-ATPase AND THE
COMPLICATIONS OF DIABETES
There are several lines of evidence suggesting that the abil-
ity of C-peptide substitution to prevent and maybe to reverse
some complications of diabetes is mediated by the restoration
of Na+,K+-ATPase activity.
Indeed, abnormalities in this enzyme activity appear impli-
cated in a variable extent in the pathogenesis of many compli-
cations of diabetes.
Erythrocyte Dysfunction
It is well known that the properties of diabetic erythro-
cytes are abnormal (Juhan et al., 1982; Finotti and Verbaro,
1987). These abnormalities include decreased deformabilityC-PEPTIDE, Na+,K+-ATPase, AND DIABETES 45
(McMillan,1975;VagueandJuhan,1983)increasedmembrane
viscosity (Baba et al., 1979) and increased erythrocyte aggre-
gation (Schmid-Schonbein and Volger, 1976). The decreased
Na+,K+-ATPase activity observed in the diabetic erythrocyte
membrane leads to an intra cellular accumulation of sodium
withsubsequentaccumulationoffreecalciumionsduetocom-
petition in transmembranous exchange (Gardner and Bennett,
1986) and may be responsible for the decreased deformability.
Indeed,attenuationofNa+,K+-ATPaseactivityhasbeenshown
to correlate with decreased deformability in diabetic erythro-
cyte (Finotti and Verbaro, 1987). Incubation with C-peptide
restores their deformability. It appears Na+,K+-ATPase medi-
ated as a pretreatment by ouabain a speciﬁcN a +,K+-ATPase
inhibitor suppresses entirely the beneﬁcial effect of C-peptide
(Kunt et al., 1999).
Nerve Function
In experimental diabetic neuropathy, a decrease in nerve
conduction velocity (NCV) has been widely reported (Sima
andSugimoto,1999).Amongthehypotheticalmechanisms,the
importance of a decrease in Na+,K+-ATPase activity has been
actively debated (Greene and Lattimer, 1983; Cameron et al.,
1994). A sciatic nerve decrease in this enzyme activity could
alter the normal membrane axon repolarization after the depo-
larization induced by an action potential, and one could expect,
therefore,adecreaseinNCV.WrightandNukada(1994)found
signiﬁcant reductions in NCV 16 weeks after diabetes induc-
tion, with trends apparent after 4 weeks. Because diabetes was
inducedinmatureratsinthisstudy,therewasadelaybeforethe
NCV decrease became signiﬁcant. Indeed, when diabetes was
induced in growing rats, a signiﬁcant decrease in NCV was ob-
served as early as 2 weeks (Mizuno et al., 1999; Coppey et al.,
2000). Disturbances in Na+,K+-ATPase activity in the sciatic
nerve have been proposed to be partially but not fully responsi-
ble for the slowing of nerve conduction velocity in the diabetic
rat, because in some studies, the slowing of motor NCV seems
to precede the decrease in enzyme activity (Lambourne et al.,
1988; Wright and Nukada, 1994). In studies from our labora-
tory,wealwaysobserveapartialrestorationofNa+,K+-ATPase
activity associated with either a partial (Gerbi and Maixent,
1999; Gerbi et al., 1999) or a total (Coste et al., 1999) restora-
tion of conduction velocity in sciatic nerve of diabetic rats after
varioustherapeuticinterventions,suchasgamma-linolenicacid
orﬁshoilsupplementation.Inaddition,Coppeyandcolleagues
(2000) showed that the temporal decrease between these two
parameters was similar, although the decrease in motor NCV
became signiﬁcant more rapidly (14 days) than the decrease
in Na+,K+-ATPase activity (28 days). All these observations
argueforapartialimplicationofadecreaseinNa+,K+-ATPase
as the cause of the diabetes-induced decrease in NCV.
Decrease Na+,K+-ATPase activity is associated with in-
creased inactivation of sodium channels and intra-axonal
sodium accumulation at the node, resulting in paranodal
swelling (Sima and Sugimoto, 1999). C-peptide administra-
tion, which restores Na+,K+-ATPase activity, prevents and re-
pairsnodalandparanodalchangesininsulinopenicdiabeticrats
(Sima et al., 2001). In the same way, ﬁsh oil administration to
streptozotocin-induced diabetic rats restores, in parallel, nerve
Na+,K+-ATPase activity and NCV, and prevents the nerve his-
tological damage (endoneural edema and axonal degeneration)
(Gerbi et al., 1999).
Althoughindirect,thesedatasupportthehypothesisofapar-
tial causative role of impaired Na+,K+-ATPase activity in dia-
betic polyneuropathy. The beneﬁcial C-peptide effect is prob-
ably mediated by the improvement of ATPase activity together
with that on nerve blood ﬂow.
Renal Function
The initial repercussion of diabetes on renal function are
characterized by a glomerular hyperﬁltration, a defect in the
controlofnatriuresis,withadecreasedresponsivenesstoantid-
iuretic hormone and later on a microalbuminuria (Zerbe et al.,
1979;WaldandPopovtzer,1984;Tuckeretal.,1993;McKenna
et al., 1999, 2000).
Short-terminfusionofC-peptideinratswithstreptozotocin-
induced diabetes resulted in reduction of glomerular hyperﬁl-
trationandmicroalbuminuria,andregressionofglomerularhy-
pertrophy (Sjoquist et al., 1998; Samnegard et al., 2001).
In humans, treatment with C-peptide reduces both glomeru-
larhyperﬁltrationandurinaryalbuminexcretioninpatientswith
type1diabetes,suggestingaspeciﬁceffectonglomerularfunc-
tionattheearlystageofdiabeticnephropathy(Johanssonetal.,
1992, 1993, 2000).
In rat MTAL, the C-peptide effects are well documented,
andinsulindisplaysonlyasmallstimulatoryeffectonNa+,K+-
ATPase and sodium reabsorption (Mandon et al., 1993), prob-
ably due to poor expression of insulin receptors (Butlen et al.,
1988). These arguments suggest strongly that in rat tubule, a
physiological amount of C-peptide exerts a hormonal effect at
a cellular level. The results in native tissue are consistent with a
contribution of C-peptide to the multihormonal stimulation of
Na+,K+-ATPaseactivityduringnonfastingperiodsandthereby
to renal sodium handling during nonfasting periods. Taken to-
gether, all these results strongly suggest that the MTAL is the
physiological target of C-peptide in the kidney.
Cardiovascular Function
Diabetes mellitus enhances the risk of morbidity and mor-
tality from cardiovascular disease. Independently of coronary46 P. VAGUE ET AL.
artery disease, the development of cardiomyopathy may
contributetothediabeticcardiacdisease(FeinandSonnenblick,
1985; Sonnenblick et al., 1985). Diabetic cardiomyopathy has
been associated with changes in enzymatic activity in the
cardiac sarcolemma with decreased Na+,K+-ATPase activity
(Imanaga, 1976; Ng et al., 1993; Gerbi et al., 1997). This de-
creasedactivityaverages30%,asinothertissuesaffectedbydi-
abetes (Gerbi et al., 1997). One may speculate that the reduced
enzyme activity impairs myocardial contractility and plays a
role in a development of diabetic cardiomyopathy (Pierce and
Dhalla, 1983; Schaffer, 1991). Indeed, it seems reasonable to
assume that intracellular sodium and potassium homeostasis is
altered.Fishoilsupplementation,whichrestoresthemembrane
ﬂuidity, has been reported to lower the risk of cardiovascular
disease (Weaver and Holub, 1987; Leaf and Weber, 1988). It
correctsimpairedheartperformanceindiabeticrat(Blacketal.,
1989) and prevents fatal ventricular ﬁbrillation induced by is-
chemia(McLennanetal.,1985,1988).Ithasbeendemonstrated
that ﬁsh oil supplementation prevents and/or restores the activ-
ity of Na+,K+-ATPase in the myocardial membrane without
changing its expression, probably by modifying its membrane
environment (Gerbi et al., 1997). It has been recently demon-
stratedthatashort-term60-minuteC-peptideinfusiontotype1
diabetic patients improves myocardial blood ﬂow and function
(Hansen et al., 2002). It is possible that this effect is related
to an improvement in the myocardium Na+,K+-ATPase activ-
ity. In the same way, it has been shown that diabetic patients
who have received an islet transplant, restoring some degree
of C-peptide secretion, have a better cardiovascular progno-
sis than the patients in whom the transplant failed, although the
glycemiccontrolwasapproximatelythesameinthetwogroups
(La Rocca et al., 2001).
CONCLUSIONS
An impairment of the enzyme Na+,K+-ATPase in many tis-
sues obtained from diabetic animals as well as in humans is
now well established. They are strong arguments suggesting
thatthisimpairmentplaysaroleinthedevelopmentofdiabetes-
associated complications.
A new aspect in the physiopathology of type 1 diabetes is
that, along side the lack of insulin, C-peptide could have, al-
though to a much lower extent, some implications. In other
terms,C-peptidehasabiologicaleffect.Thiseffectisatleastin
part mediated by a direct activation of Na+,K+-ATPase, more
exactly by a restoration of the normal enzyme activity in the
tissues of diabetic animals or humans.
If futures studies demonstrate C-peptide replacement is of
substantial clinical beneﬁt, it would probably be relatively easy
to add in the insulin vial an equimolar amount of C-peptide,
thus mimicking the insulin secretory granule.
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